Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Orlistat in Line for Approval as Japan’s 1st Nonprescription Obesity Drug after 4-Year Review
November 29, 2022
- Limit Coverage of Off-Year Re-Pricing to Drugs with Large-than-Average Price Gap: LDP Proposal
November 29, 2022
- Sanofi’s Cemiplimab Backed for Approval, Third PD-1 Inhibitor in Japan
November 29, 2022
- MHLW to Report Responses to Zolgensma Paper Retraction on Dec. 12
November 29, 2022
- MHLW Panel Endorses Teikoku’s Donepezil Tape for Alzheimer’s and More Drugs
November 28, 2022
- LDP Lawmakers’ League Holds Hearing on SaMD Review Status
November 28, 2022
- Japan to Begin Xocova Supply on Nov. 28 ahead of Schedule
November 28, 2022
- MHLW Panel OKs 111 More Health Damage Claims for COVID-19 Vaccines
November 28, 2022
- Japan Approves Label Expansion for Enhertu, TS-1, and More
November 25, 2022
- Upper House Health Committee OKs Bill to Amend Infectious Disease Act
November 25, 2022
- LDP Pharma Study Group Calls for Careful Discussions on Off-Year Plan: Proposal
November 25, 2022
- LDP Lawmakers’ League Boots Up for Medical Adhesive Patches
November 24, 2022
- LDP League Urges MEXT to Provide Accurate Info on HPV Vaccines at Medical Schools
November 24, 2022
- MOF Panel Proposal Expected to Spell Out Full Annual Price Revision
November 24, 2022
- Japan Grants 1st Emergency Approval to Shionogi COVID Pill Xocova
November 24, 2022
- Defense Buildup Won’t Impact Degree of Cuts in Social Security Costs: MHLW Official
November 22, 2022
- Bill to Amend Intractable Disease Law Passes Lower House
November 22, 2022
- Enough Antipyretic Analgesic Agents Secured for Twindemic, MHLW Says
November 21, 2022
- LDP Tax Council to Compile FY2023 Reform Proposal by Mid-December
November 21, 2022
- Govt to Designate 4 β-Lactam Antibiotics as Key Resources by Year-End
November 18, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…